The investigation focuses on assertions made by Regenxbio regarding the Phase I/II study for RGX-111, a treatment designed for Hurler Syndrome. According to a federal securities lawsuit, the company allegedly provided false or misleading information to the market, specifically concerning the drug's projected success based on biomarker data. Investors who held RGNX shares prior to February 9, 2022, are being urged to come forward as the firm evaluates potential breaches of fiduciary duty.

Kuehn Law, based in Southampton, New York, is soliciting contact from affected parties to determine the scope of the alleged misconduct. The firm has stated it covers all case costs for clients, emphasizing that shareholders should act quickly due to potential legal deadlines. Interested parties can reach out to Sophia Anne Silayan at the firm to discuss their rights and the implications of the ongoing derivative litigation.